

<b>Study title</b>	<b>Name of sponsor</b>	<b>Location for study</b>	<b>Commencement of administrative procedure</b>
GCP certificate		Quinta Analytica	No
A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)	Novartis Pharma AG	Klin Med s.r.o.	No
A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)	Pfizer Inc.	Fakultní nemocnice u sv. Anny v Brně	No
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma	Fakultní nemocnice Hradec Kralove	Fakultní nemocnice Hradec Kralove	No
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE)	AstraZeneca AB	MediTrial s.r.o.	No
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke	Amgen Inc.	MUDr. Jan Kvasnička, CSc., Ordinace pro choroby srdce a cév	No
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke	Amgen Inc.	Clinical Trials Service s.r.o.	No
Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis	Genzyme Corporation	Fakultní nemocnice Hradec Králové	No
Inspection of ethics committee		Ethics committee, Fakultní nemocnice Plzeň	No
A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis	Incyte Corporation	CTCenter MaVe s.r.o.	Yes
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 301)	Shire Human Genetic Therapies, Inc.	Institut klinické a experimentální medicíny	No
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult subjects with aneurysmal subarachnoid hemorrhage (aSAH)	Idorsia Pharmaceuticals Ltd	Ústřední vojenská nemocnice	No
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult subjects with aneurysmal subarachnoid hemorrhage (aSAH)	Idorsia Pharmaceuticals Ltd	Fakultní nemocnice Brno	No

A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects with Early Alzheimer's Disease	Eisai Ltd.	BRAIN-SOULTHERAPY s.r.o.	No
Inspection of ethics committee		Ethics committee, Nemocnice Pardubického Kraje, a.s.	No
Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR)	Masarykův onkologický ústav	Masarykův onkologický ústav	No
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTI CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF 04965842 CO ADMINISTERED WITH BACKGROUND MEDICATED TOPICAL THERAPY IN ADOLESCENT PARTICIPANTS 12 TO <18 YEARS OF AGE WITH MODERATE TO SEVERE ATOPIC DERMATITIS	Pfizer Inc.	Kožní ambulance Kutná Hora,s.r.o.	No
A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients with, or at high risk for, Cardiovascular Disease who are Statin Intolerant	Esperion Therapeutics Inc.	Oblastní nemocnice Kolín, a. s., nemocnice Středočeského kraje	No
A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group, Phase 3 study to assess the efficacy and safety of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia (DCI), in adult subjects with aneurysmal subarachnoid hemorrhage (aSAH)	ObsEva S.A.	MUDr. Lubomír Mikulášek	No
Non-inferior efficacy of Nystatin oral gel and Nystatin oral suspension compared to reference Mycostatin oral suspension in adult patients with oropharyngeal candidiasis	VUAB Pharma a.s.	Alergologická ambulance MUDr. Ján Kalanin	No
Non-inferior efficacy of Nystatin oral gel and Nystatin oral suspension compared to reference Mycostatin oral suspension in adult patients with oropharyngeal candidiasis	VUAB Pharma a.s.	Alergologie Třeboňská s.r.o.	Yes